Ignite Creation Date:
2024-05-06 @ 10:03 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03144856
Status:
UNKNOWN
Last Update Posted:
2017-05-09
First Post:
2017-05-05
Brief Title:
Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer
Status:
UNKNOWN
Status Verified Date:
2017-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers
Detailed Description:
Biliary tract cancers BTC includes cholangiocarcinoma and gallbladder carcinoma GBC The systematic treatment based on gemcitabine plus cisplatin is recommended as the current standard chemotherapy for unresectable or metastatic BTC There is no standard recommendation for second line therapy
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2VEGFR-2
This study was conducted to assess the efficacy and safety of Apatinib in patients with advanced refractory BTC who had received first-line chemotherapy
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2VEGFR-2
This study was conducted to assess the efficacy and safety of Apatinib in patients with advanced refractory BTC who had received first-line chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None